文献速递类风湿关节炎

类风湿因子、抗瓜氨酸化蛋白抗体及共享表位与早期类风湿关节炎初始治疗临床缓解的关联:一项随机对照试验数据

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial.
PubMed 文献 · Ann Rheum Dis · 2024-11-14

基于NORD-STAR随机对照试验的778例未治疗早期类风湿关节炎患者,分析RF、ACPA及SE等位基因相关遗传标志与阿巴西普、聚乙二醇化赛妥珠单抗或托珠单抗对比积极传统治疗疗效的关联。24周时阿巴西普在RF和/或ACPA阳性亚组中疗效优于积极传统治疗,但48周时该差异不再显现;SE等位基因相关标志未增强上述关联。

要点

  • 24周时阿巴西普在RF和/或ACPA阳性亚组中疗效优于积极传统治疗,但与阴性亚组间差异无统计学显著。
  • 48周时阿巴西普疗效优于积极传统治疗,且不受RF/ACPA状态影响。
  • 48周时各生物制剂在RF、ACPA、SE等位基因等亚组间均未发现疗效差异。

核心结论

  • 基于本随机对照试验,24周时阿巴西普在RF和/或ACPA阳性亚组中疗效优于积极传统治疗,但48周时该差异不再显现。
  • 加入SE等位基因相关遗传标志并未增强上述关联。
  • ACPA、RF及SE等位基因相关基因型单独或联合均与具有重要临床意义的疗效关联不够强,不足以支持应用于临床实践。

研究设计与样本

  • NORD-STAR随机对照试验,纳入未治疗的早期类风湿关节炎患者778例,随机分配至积极传统治疗、聚乙二醇化赛妥珠单抗、阿巴西普或托珠单抗,均联合甲氨蝶呤。
  • 集中实验室检测ACPA、RF及SE,采用logistic广义估计方程纵向分析临床疾病活动指数缓解。
  • 在24周和48周通过交互项评估RF、ACPA及SE亚组间治疗效应差异,校正性别、国家、年龄、体重指数、基于C反应蛋白的28关节疾病活动评分及吸烟。

主要发现

  • 24周时阿巴西普在RF和/或ACPA阳性亚组中疗效优于积极传统治疗,但该效应与阴性亚组间无显著差异。
  • 48周时阿巴西普疗效优于积极传统治疗,且不受RF/ACPA状态影响。
  • 48周时任何生物制剂在RF、ACPA、SE等位基因、第11位氨基酸缬氨酸或缬氨酸-精氨酸-丙氨酸单倍型亚组间均未发现差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate whether rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPAs) and shared epitope (SE) allele-related genetic markers associate with treatment response to abatacept, certolizumab pegol or tocilizumab versus active conventional treatment (ACT). METHODS: Patients with treatment-naïve early rheumatoid arthritis were randomised in the NORD-STAR trial to ACT, certolizumab pegol, abatacept or tocilizumab, all with methotrexate. Centralised laboratory analyses for ACPA, RF and SE were performed. Clinical Disease Activity Index remission was analysed longitudinally with logistic generalised estimating equations. Differences in treatment effect across RF, ACPA and SE subgroups were assessed with interaction terms at 24 and 48 weeks, adjusted for sex, country, age, body mass index, Disease Activity Score of 28 joints based on C-reactive protein and smoking. RESULTS: In total, 778 patients were included. At 24 weeks, abatacept treatment showed a better response than ACT in the RF and/or ACPA-positive subgroups, but this effect was not significantly different from the negative subgroups. By 48 weeks, abatacept treatment showed better response regardless of RF/ACPA status. No differences were found across RF, ACPA, SE allele, valine at amino acid position 11 or valine-arginine-alanine haplotype subgroups for any biological treatment at 48 weeks. CONCLUSIONS: Based on this randomised controlled trial, abatacept treatment was associated with a better response than ACT in the RF and/or ACPA-positive subgroup at 24 weeks, but this was no longer seen at 48 weeks; adding SE allele-related genetic markers did not strengthen the association. Moreover, ACPA, RF and SE allele-related genotypes were not, alone or in combination, associated with clinical responses of importance sufficiently strongly to warrant implementation in clinical practice. TRIAL REGISTRATION NUMBER: EudraCT 2011-004720-35; ClinicalTrials.gov NCT01491815.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Lend K, Lampa J, Padyukov L, et al. Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial. Ann Rheum Dis. 2024. PMID: 39079894. doi:10.1136/ard-2024-226024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。